AROVELLA THERAPEUTICS LIMITED
ASX:ALAPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 85.8% of what they think they own, once every option and right converts.
3 cash raises in 24 months; runway 4–8 quarters; options/rights overhang 16% of shares
AROVELLA THERAPEUTICS LIMITED's ordinary share count grew 14.9% between July 2024 and June 2026, reaching 1.21B shares. In the past 24 months, the company completed three capital raises totalling A$15.8M, with the most recent being a A$15.0M placement in February 2025. There are potential new shares of 200M from options and rights, representing 16.5% of the current share count, with the nearest expiry in May 2027; none of these are currently in the money. As of the June 2026 quarter, AROVELLA THERAPEUTICS LIMITED had A$12.2M in cash, sufficient for approximately 4.6 quarters of operations. No proposed securities issues are currently pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 17 Aug 2026 | 3G · unquoted | ORDINARY FULLY PAID | 1.21B | Appendix 3G |
| 29 June 2026 | 2A · quoted issue | ALA : ORDINARY FULLY PAID | 1.21B | Appendix 2A |
| 29 June 2026 | 3H · cancellation | ALA : ORDINARY FULLY PAID | 1.21B | Appendix 3H |
| 25 May 2026 | 3H · cancellation | ALA : ORDINARY FULLY PAID | 1.21B | Appendix 3H |
| 7 May 2026 | 3H · cancellation | ALA : ORDINARY FULLY PAID | 1.21B | Appendix 3H |
Capital raises
3 cash raises in the last 24 months · 0 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
An exercise price is on record for only 22.0% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.061 today. At double today’s price it is 44.0M (3.6% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 155.8M (78.0% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ALAO | Options | Price-triggered | — | 24 May 2027 | 155.8M | Filing |
| ALAAA | Options | Price-triggered | $0.10 | — | 44.0M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 9 June 2026 | David John Williams | Buy on-market | 200k | — | — | $13k | 3Y notice |
| 24 Nov 2025 | Elizabeth Stoner | Other | 1.2M | — | — | — | 3Y notice |
| 12 Nov 2025 | Debora Barton | Buy | 1.0M | 1.4M | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.